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Abeta is targeted to the vasculature in a mouse model of
hereditary cerebral hemorrhage with amyloidosis
Abstract
The E693Q mutation in the amyloid beta precursor protein (APP) leads to cerebral amyloid angiopathy
(CAA), with recurrent cerebral hemorrhagic strokes and dementia. In contrast to Alzheimer disease
(AD), the brains of those affected by hereditary cerebral hemorrhage with amyloidosis-Dutch type
(HCHWA-D) show few parenchymal amyloid plaques. We found that neuronal overexpression of
human E693Q APP in mice (APPDutch mice) caused extensive CAA, smooth muscle cell degeneration,
hemorrhages and neuroinflammation. In contrast, overexpression of human wild-type APP (APPwt
mice) resulted in predominantly parenchymal amyloidosis, similar to that seen in AD. In APPDutch
mice and HCHWA-D human brain, the ratio of the amyloid-beta40 peptide (Abeta40) to Abeta42 was
significantly higher than that seen in APPwt mice or AD human brain. Genetically shifting the ratio of
AbetaDutch40/AbetaDutch42 toward AbetaDutch42 by crossing APPDutch mice with transgenic mice
producing mutated presenilin-1 redistributed the amyloid pathology from the vasculature to the
parenchyma. The understanding that different Abeta species can drive amyloid pathology in different
cerebral compartments has implications for current anti-amyloid therapeutic strategies. This HCHWA-D
mouse model is the first to develop robust CAA in the absence of parenchymal amyloid, highlighting
the key role of neuronally produced Abeta to vascular amyloid pathology and emphasizing the differing
roles of Abeta40 and Abeta42 in vascular and parenchymal amyloid pathology.
Mutations in APP at the β- and γ-secretase sites have been shown to
cause familial forms of early-onset AD. These mutations increase the
production of either total amyloid-β peptides (Aβ) or the more amy-
loidogenic Aβ1–42 species. In contrast, most mutations within the Aβ
domain do not result in a full range of AD pathology but characteris-
tically result in cerebrovascular pathology1–3. For example, the E693Q
point mutation in APP (affecting residue 22 of Aβ) results in
HCHWA-D, an autosomal-dominant form of CAA4,5. Those afflicted
with HCHWA-D suffer from recurrent lobar cerebral hemorrhages,
with an onset in the fifth decade of life6. At autopsy, extensive CAA is
typically found in leptomeningeal arteries and cortical arterioles, and
to a lesser extent in meningocortical veins. Unlike in AD, parenchymal
amyloid plaques are not prominent in HCHWA-D, although diffuse
parenchymal Aβ is found7. Because of these features of the disease,
HCHWA-D has become the human genetic archetype of the Aβ con-
gophilic angiopathy seen sporadically in many of the elderly and in
the majority of those with AD8,9.
Previous in vitro findings have shown that Aβ harboring the Dutch
E693Q mutation (AβDutch) has been associated with enhanced
aggregation properties, reduced clearance from the brain and greater
toxicity in smooth muscle cells, as compared to wild-type Aβ
(Aβwt)10–14. However, the reasons for the predominant cerebral vas-
cular amyloid deposition in HCHWA-D are unclear. In the present
study, we generated human APP E693Q transgenic mice (APPDutch
mice) to study the mechanisms underlying vascular amyloidosis and
the consequences of CAA using an in vivo model system.
RESULTS
Aβ1–40 predominates in vascular amyloid in HCHWA-D
Cerebrovascular amyloid in human HCHWA-D postmortem brain
tissue was found predominantly in the leptomeningeal and cortical
vessel walls, often with limited labeling of diffuse parenchymal Aβ
deposits (Fig. 1a). Immunohistochemical staining with C termi-
nus–specific antibodies to Aβ suggest that Aβ40 predominates over
Aβ42 in the cerebrovascular amyloid (Fig. 1b,c). To confirm this and
to determine whether AβDutch is the predominant Aβ species
deposited in the vessel wall, we used bicine/Tris/urea SDS-PAGE15
to separate various Aβ species. Both HCHWA-D cortical tissue and
isolated leptomeningeal vessels contained abundant AβDutch1–40
as well as substantial amounts of Aβwt1–40 (Fig. 1d). In contrast, in
the brains of individuals with sporadic AD, both Aβ1–40 and
Aβ1–42 were present (Fig. 1d). These observations were confirmed
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hereditary cerebral hemorrhage with amyloidosis
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The E693Q mutation in the amyloid beta precursor protein (APP) leads to cerebral amyloid angiopathy (CAA), with recurrent
cerebral hemorrhagic strokes and dementia. In contrast to Alzheimer disease (AD), the brains of those affected by hereditary
cerebral hemorrhage with amyloidosis–Dutch type (HCHWA-D) show few parenchymal amyloid plaques. We found that neuronal
overexpression of human E693Q APP in mice (APPDutch mice) caused extensive CAA, smooth muscle cell degeneration,
hemorrhages and neuroinflammation. In contrast, overexpression of human wild-type APP (APPwt mice) resulted in
predominantly parenchymal amyloidosis, similar to that seen in AD. In APPDutch mice and HCHWA-D human brain, the ratio of
the amyloid-β40 peptide (Aβ40) to Aβ42 was significantly higher than that seen in APPwt mice or AD human brain. Genetically
shifting the AβDutch40/AβDutch42 ratio toward AβDutch42 by crossing APPDutch mice with transgenic mice producing
mutated presenilin-1 redistributed the amyloid pathology from the vasculature to the parenchyma. The understanding that
different Aβ species can drive amyloid pathology in different cerebral compartments has implications for current anti-amyloid
therapeutic strategies. This HCHWA-D mouse model is the first to develop robust CAA in the absence of parenchymal amyloid,
highlighting the key role of neuronally produced Aβ to vascular amyloid pathology and emphasizing the differing roles of Aβ40
and Aβ42 in vascular and parenchymal amyloid pathology.
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by ELISA, which showed only half as much Aβ40 as Aβ42 in AD
brain tissue, and 18 times more Aβ40 than Aβ42 in HCHWA-D
brain tissue (Table 1).
Neuronal overexpression of human E693Q APP leads to CAA 
To understand the pathogenesis of HCHWA-D and the mechanisms
leading to cerebrovascular amyloid, we generated transgenic mice
(APPDutch mice) overexpressing E693Q-mutated human APP (hAPP)
under the control of the neuron-specific Thy1 promoter element. High
levels of hAPP mRNA were detected in neocortex, hippocampus and
brain stem by in situ hybridization (Fig. 2a). Consistently, immunohisto-
chemistry revealed robust hAPP expression in the same brain regions,
exclusively within neurons and neuronal processes. No hAPP mRNA or
protein was detected in vessel walls (Fig. 2b). We selected two transgenic
lines with high hAPP expression levels that remained constant with aging
(Fig. 2c). By direct western blot analysis, AβDutch could not be detected
in young APPDutch mice.AβDutch1–40, however, was readily detectable
in a 23-month-old mouse, consistent with amyloid deposition at this age
(Fig. 2c). Morphological analysis of APPDutch mice between 22 and 30
months of age (n = 30) showed an onset of vascular amyloid deposition
at approximately 22–25 months for both lines.Amyloid deposition in the
brain was largely confined to the cerebral vasculature (Fig. 2d), appearing
first in leptomeningeal vessels followed by cortical vessels. Female mice
seemed to have an earlier onset than males. Similar to human HCHWA-
D brain tissue and consistent with the western blot analysis, immunore-
activity for Aβ40 was much more intense than for Aβ42 (Fig. 2e,f).
Congo red (Fig. 2g) and Thioflavin S staining (data not shown) demon-
strated that much of the cerebrovascular amyloid was in a compact β-
pleated sheet conformation. Some amyloid-laden vessels showed a
vessel-within-vessel configuration (Fig. 2h). With an electron micro-
scope, we observed an irregular thickening of the basement membrane
with amorphous material in some vessels, whereas others contained
amyloid fibrils within the basement membrane—predominantly on the
adventitial side—and the endothelial cell layer appeared to be intact. At a
more advanced stage, amyloid fibrils were observed in a radial pattern
between the smooth muscle cells, with some fibrils invading the
parenchyma (Fig. 2i). Despite a substantial vascular amyloid burden,
APPDutch mice did not develop compact parenchymal amyloid plaques
and only rarely were diffuse parenchymal Aβ deposits observed.
CAA induces hemorrhages and neuroinflammation
Amyloid-laden vessels in APPDutch mice show a severe loss of smooth
muscle cells (Fig. 3a,b). Consistent with the loss of smooth muscle cells
and a concomitant weakening of the vessel walls, fresh hemorrhages
(Fig. 3c,d), as well as indications of previous hemorrhages (Fig. 3e,f),
were found in three of the oldest APPDutch mice. No bleeding was
found in age-matched, nontransgenic mice (data not shown).
In APPDutch mice with CAA, a strong, perivascular microglial
inflammatory reaction was observed (Fig. 3g). This microgliosis was
confined to the immediate vicinity of amyloid-laden vessels and was
absent in locations adjacent to unaffected vessels (Fig. 3h). In addition,
an activation of astrocytes was observed throughout all neocortical
areas affected by CAA (Fig. 3i) but not in brain areas devoid of vascular
amyloid and in nontransgenic control mice (Fig. 3j). The widespread
astrocytosis in areas affected with CAA may be the result of partial
ischemia and a perfusion deficit associated with amyloid-laden vessels.
Increased Aβ40/Aβ42 ratio in APPDutch versus APPwt mice
To examine the determinants that lead to vascular versus parenchy-
mal amyloid deposition, we compared the pattern of amyloid depo-
sition in APPDutch mice with that of transgenic mice
overexpressing wild-type hAPP at levels similar to the APPDutch
mice, under the control of the same Thy1 promoter element and in
the same C57BL/6J genetic background (APPwt mice). Aged APPwt
mice developed parenchymal plaques with limited vascular deposits
(Fig. 4a). Western blot analysis of APPwt mice with amyloid
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Figure 1  Vascular amyloid in HCHWA-D brain consists of both AβDutch and
Aβwt, with Aβ1–40 being the predominant peptide. (a) Frontal cortex of the
brain of an individual (50 years of age) with HCHWA-D immunostained with
antibody NT12 to Aβ. Massive amyloid deposition within leptomeningeal and
cortical vessel walls is observed. Only few and diffuse parenchymal Aβ deposits
are visible (arrowhead), although pretreatment may increase parenchymal
staining50. (b,c) Immunolabeling of vascular amyloid with antibodies specific to
Aβx–40 (R208 in b) and Aβx–42 (R306 in c) reveals that the majority of
vascular amyloid ends at amino acid 40. (d) Western blotting of brain
homogenates. Synthetic Aβ is shown in lanes 1–3. Homogenates of frontal
cortex (lanes 4 and 5) and pia (lanes 6 and 7) of  HCHWA-D patients contain
both Aβwt1–40 and AβDutch1–40, but no detectable Aβwt1–42 or
AβDutch1–42. This observation suggests that cerebrovascular amyloid in
HCHWA-D patients consists of both Aβwt and AβDutch and is predominantly of
the Aβ1–40 isoform. Control individuals showed no detectable Aβ (lane 8),
whereas both Aβwt1–40 and 1–42 were found in patients with sporadic AD
patients (lane 9). Scale bars are 100 µm (a) and 50 µm (b,c).
Table 1 Aβ40/Aβ42 ratios in brains of transgenic mice and
humans with HCHWA-D and AD
Human Aβ40/Aβ42 Murine Aβ40/Aβ42
Predepositing Depositing Depositing
APPwt 4.3 ± 0.3 2.8 ± 0.4 1.1 ± 0.1
APPDutch 7.8 ± 0.9** 12.1 ± 1.4*** 3.0 ± 0.5**
APPDutch/PS45 0.4 ± 0.9 0.4 ± 0.02
HCHWA-D 18.6 ± 7.0
AD 0.5 ± 0.19
Levels of human and murine Aβ40 and Aβ42 were determined by ELISA in Aβ-
depositing 18-month-old APPwt mice and 28-month-old APPDutch mice (n = 5–11).
Human Aβ was measured in predepositing 7-month-old APPwt and APPDutch mice (n =
6–9), in predepositing 3-month-old and Aβ-depositing 9-month-old APPDutch/PS45
mice, and in AD and HCHWA-D patients (n = 3–9). Data are the means of the individual
Aβ40/Aβ42 ratios ± s.e.m. **P < 0.01, ***P < 0.001 (comparison with APPwt).
Absolute Aβ values are reported in Supplementary Table 1 online.
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deposits revealed the presence of both Aβwt1–40 and Aβwt1–42,
whereas in APPDutch mice, AβDutch1–40 was seen but
AβDutch1–42 was below detection level (Fig. 4b). This was con-
firmed by ELISA, which revealed a more than fourfold higher
human Aβ40/Aβ42 ratio in APPDutch mice than in APPwt mice
(Table 1; for absolute values, see Supplementary Table 1 online). We
also analyzed steady-state levels of Aβ40 and Aβ42 in APPDutch
and APPwt mice at 7 months, before detectable amyloid deposition,
to determine whether this difference in the ratio of Aβ40 to Aβ42 is
an early event or is only seen after the accumulation of amyloid. An
almost twofold greater Aβ40/Aβ42 ratio was seen in young
APPDutch mice than in APPwt mice of similar age (Table 1 and
Supplementary Table 1).
Massive parenchymal amyloid in APPDutch/PS45 mice
Examining our hypothesis that a high ratio of AβDutch1–40 to
AβDutch1–42 is linked to and potentially necessary for the predomi-
nant vascular amyloid deposition in APPDutch mice, we crossed
APPDutch mice with mice that overexpress human presenilin-1
(PS1) bearing the G384A mutation (PS45 mice). This mutation is
known to increase Aβ1–42 production16,17. Notably, starting at 12
weeks of age, APPDutch/PS45 double-transgenic mice developed
parenchymal amyloid in the neocortex and hippocampus. At 10
months, massive diffuse and compact parenchymal amyloid was
found in virtually all brain regions. Unlike in the APPDutch mice,
vascular amyloid, although present, was a much less prominent fea-
ture in the APPDutch/PS45 mice (Fig. 5a).
Western blot analysis of APPDutch/PS45 brain homogenates revealed
abundant AβDutch1–42 in addition to AβDutch1–40 (Fig. 5b). ELISA
measurements confirmed this observation, with AβDutch42 at least
twice as abundant as AβDutch40 in double-transgenic mice, both before
(predepositing) and after (depositing) the onset of amyloid deposition
(Table 1 and Supplementary Table 1). These results demonstrate that
AβDutch is capable of forming parenchymal amyloid deposits and that
A R T I C L E S
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Figure 2  APPDutch mice develop cerebral
amyloid angiopathy. (a) In situ hybridization
reveals high transgene-derived mRNA levels in
neocortex (ctx) and hippocampus (hi) and brain
stem. (b) Immunostaining for hAPP in neocortex
shows punctate labeling of neuronal perikarya
(arrowhead) and weaker labeling of axonal
processes. Consistent with the neuron-specific
promoter, there was no hAPP expression in the
vessel wall (the lumen of the vessel is indicated
by an asterisk). (c) Western blot analysis of hAPP
and hAβ in mouse brain using an antibody
specific to human APP/Aβ. Upper panel:
APPDutch expression in APPDutch mouse lines
23 (lane 4) and 33 (lanes 5 and 7) and a
nontransgenic control littermate (lane 6). Bands
demonstrate immature and mature forms of
hAPP. Lower panel: synthetic human Aβwt1–40
mixed with human Aβwt1–42, AβDutch1–40 and
AβDutch1–42 peptides were used as markers
(lanes 1–3). Aβ levels did not reach detection
levels in predepositing APPDutch mice without
immunoprecipitation (shown are 13-month-old
mice). In contrast, in a 23-month-old amyloid
depositing APPDutch mouse, AβDutch1–40, but
not AβDutch1–42, was readily detected (lane 7).
(d) Immunohistochemical analysis of a 29-
month-old APPDutch mouse shows Aβ deposition
largely confined to leptomeningeal and
neocortical vessels (NT12 antibody). No compact
parenchymal deposits were seen. (e,f)
Immunolabeling of vascular amyloid with
antibodies specific to Aβ40 (R208 in e) and
Aβ42 (R306 in f) reveals that the majority of
vascular amyloid ends at amino acid 40.
(g) Congo red staining of amyloid-laden vessels
demonstrates that the vast majority of the
amyloid is of compact nature and congophilic.
(h) High-magnification view of amyloid-
containing cortical vessels that shows a vessel-
within-vessel configuration. (i) Electron
micrograph demonstrating abundant amyloid
fibrils (asterisk) between the smooth muscle
cells (SMC) in a 30-month-old APPDutch mouse.
Scale bars are 1 mm (a), 10 µm (b, e–h), 200
µm (d) and 1 µm (i). 
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such deposits can be induced in APPDutch mice by increasing the pro-
duction of AβDutch42 via the expression of mutant presenilin.
Endogenous murine Aβ is codeposited with human Aβ
To determine whether endogenous murine Aβ, the counterpart of Aβwt
derived from the wild-type allele in individuals with HCHWA-D, is
codeposited with transgene-derived human Aβ in APPDutch mice, we
used ELISA specific for murine Aβ40 and Aβ42. The amount of murine
Aβ was 4.4 ± 0.1% of the human Aβ detected in APPwt mice and 8.0 ±
1.0% of that detected in APPDutch mice. Notably, depositing APPDutch
mice showed a roughly threefold higher ratio of murine Aβ40 to Aβ42
than was seen in APPwt mice (Table 1 and Supplementary Table 1).
DISCUSSION
Although the APP mutation that causes HCHWA-D was identified
more than a decade ago4, progress toward understanding the pathogen-
esis of HCHWA-D has been hampered by the absence of an animal
model. Here we describe a transgenic mouse model that develops
extensive cerebrovascular amyloid deposits in leptomeningeal and cor-
tical vessels, similar to those found in affected people5,7. Parenchymal
amyloid is nearly absent in these transgenic mice, and the few
parenchymal plaques found are diffuse. The observation that neuronal
expression of APPDutch is sufficient for cerebrovascular amyloidosis,
smooth muscle cell degeneration and hemorrhage in a mouse model
strongly suggests that neurons are the source of the cerebrovascular
amyloid in HCHWA-D. Moreover, these results demonstrate that
smooth muscle cell degeneration does not require intracellular Aβ pro-
duction but can be initiated by extracellular, neuron-derived Aβ that is
transported to and accumulates at the vasculature.
Expanding on previous research18,19, we
found that amyloid deposits in human
HCHWA-D brains contain not only
AβDutch40 but also abundant Aβwt40, with
only little Aβ42. In the APPDutch mice, as in
human HCHWA-D, the vast majority of the deposited Aβ is Aβ40, with
roughly 12 times more AβDutch40 than AβDutch42. This is in contrast
to the peptide ratios found in human AD and in APPwt mice or other
transgenic mice expressing Swedish APP, where significantly more
Aβ42 relative to Aβ40 is deposited20–23. In both HCHWA-D brain tis-
sue and APPDutch mice, Aβwt derived from the wild-type allele in
HCHWA-D and from the endogenous murine APP in the APPDutch
mice followed the deposition pattern of the mutated AβDutch species.
The two other mouse models we have examined in this study further
highlight the important role of the Aβ40/Aβ42 ratio in determining
vascular versus parenchymal amyloid deposition. APPwt mice overex-
pressed APP at levels comparable to APPDutch mice, but the former
developed abundant parenchymal plaques and only sparse vascular
amyloidosis, suggesting that the single E693Q amino acid substitution
is sufficient to target neuron-derived Aβ to the vessel wall. Notably, the
Aβ40/Aβ42 ratio was significantly lower in APPwt mice than in
APPDutch mice. Thus, a straightforward explanation for why the
Dutch mutation leads to CAA could be that it favors the production of
Aβ40, which in turn is vasculotropic. To examine this hypothesis, we
determined the Aβ40/Aβ42 ratio in young transgenic mice before the
onset of amyloid deposition, where a twofold higher ratio of
Aβ40/Aβ42 was seen in APPDutch mice than in APPwt mice. In condi-
tioned media of E693Q transfected cells, a similar, albeit somewhat
smaller, increase in the Aβ40/Aβ42 ratio has been reported11,24. This
suggests that the Dutch mutation affects Aβ40/Aβ42 ratios at the level
of Aβ production or clearance. Recent results show that AβDutch40 is
more resistant to proteolysis by both neprilysin and insulin-degrading
enzyme25,26 and is less efficiently cleared into the blood13 than Aβwt40.
Similar studies with AβDutch42, however, have not been reported.
A R T I C L E S
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Figure 3  Hemorrhages and neuroinflammation in
APPDutch mice. (a) Double labeling for smooth
muscle cell actin (green) and Aβ (red) in a
leptomeningeal vessel of a 29-month-old
APPDutch mouse reveals displacement of
smooth muscle cells by vascular amyloid
(arrowheads).(b) Vessels that are not affected by
Aβ show a continuous rim of smooth muscle
cells. Shown are superpositions of optical
sections. (c) A fresh hemorrhage is shown that
occurred at the surface of the brain of a 29-
month-old APPDutch mouse. (d) Hematoxylin
and eosin (H&E) staining on a cross-section
through the bleeding shown in c. (e)
Microhemorrhage associated with amyloid-laden
vessels visualized by Perls’ Prussian blue
staining for ferric iron. (f) High magnification of
such microbleeds reveal hemosiderin-positive
microglia. (g) Activated perivascular microglia
(blue) in the immediate vicinity of amyloid-laden
vessels (Congo red) in the neocortex of a 29-
month-old APPDutch mouse. (h) Such
microgliosis was absent in the same mouse
around unaffected vessels (arrowheads). 
(i) Reactive astrocytes (blue) in neocortical areas
with CAA (Congo red). (j) In neocortical regions
with no vascular amyloid, no reactive astrocytes
were observed. Scale bars are 20 µm (a,b,e),
100 µm (c,g–j), 50 µm (d) and 5 µm (f).
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Familial AD-causing PS1 mutations shift the generation of Aβ to
favor Aβ42, which results in early and robust parenchymal amyloid
deposition in transgenic mice that produce human wild-type
Aβ16,27,28. Crossing the APPDutch mouse with the PS45 line resulted
in abundant parenchymal plaque formation at a young age, with lim-
ited CAA pathology. Thus, although AβDutch preferentially accumu-
lates around cerebral vessels, genetically shifting the AβDutch40/
AβDutch42 ratio to favor AβDutch42 was sufficient to alter the distri-
bution of the resulting amyloid pathology from the vasculature to the
parenchyma. Moreover, this demonstrates that AβDutch can form
dense and congophilic plaques within the parenchyma. Therefore,
parenchymal amyloid formation in APPDutch mice and humans with
HCHWA-D is likely to be limited by the absence of Aβ42-driven
parenchymal amyloid seeding. The present data do not rule out a role
for Aβ42 as seed for vascular amyloid29.
We have previously shown that cerebral amyloidosis is not a local
process and that Aβ can be transported extracellularly and accumu-
late distant to its site of production30, as must also occur in the
APPDutch mouse. This observation, together with the finding of sim-
ilar intraneuronal Aβ accumulation in APPDutch and APPwt trans-
genic mice (Supplementary Fig. 1 online), indicate that different Aβ
species interact differently with the extracellular environment, mak-
ing Aβ movement through the different local environments in the
CNS an important determinant of amyloid pathology. For instance,
when Aβ42 concentration is insufficient to form and maintain
parenchymal amyloid seeds, soluble Aβ is transported from neurons
to the vasculature, where it is cleared into the blood or drained along
perivascular spaces31,32. Coupled with the observation that
AβDutch40 is less efficiently cleared than Aβwt40 is13, this may in
part explain why AβDutch40 accumulates at the vessel wall in
APPDutch mice, whereas it can accumulate within the parenchyma
when these mice are crossed with PS45 mice.
The knowledge that both Aβ40 and Aβ42 have the potential to drive
amyloid pathology, albeit within different compartments, will
undoubtedly have further implications as anti-Aβ therapies are devel-
oped. For example, anti-Aβ immunotherapy has been shown to pref-
erentially clear Aβ42 from mice with preexisting amyloid
pathology33,34. Although selective clearance of Aβ42 would benefi-
cially reduce parenchymal amyloid burden, this might potentiate vas-
cular amyloid pathology, as has been alluded to in Aβ-immunotherapy
studies done in mice and may also have been the case for the two
Aβ42-immunized human patients who have gone to autopsy33,35–37.
Given this complexity, further studies of anti-Aβ therapies will need to
follow alterations in the Aβ40/Aβ42 ratio, while addressing the result-
ing balance of vascular and parenchymal amyloid pathology.
Most individuals with HCHWA-D die early due to recurrent
strokes6, but some with relatively restricted stroke pathology reach a
considerable age. Nevertheless, these individuals show a continuous
cognitive decline similar to that seen in persons with AD38. This sup-
ports recent studies suggesting that CAA is not only a significant cause
of intracerebral hemorrhage in the elderly but also an important con-
tributing factor to cognitive impairment and AD dementia39. CAA may
interfere with the anatomical integrity of the vessel wall and the physio-
A R T I C L E S
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Figure 4 Parenchymal and vascular amyloid deposition in APPwt mice. 
(a) Aβ-immunostaining of an 18-month-old APPwt mouse reveals
parenchymal amyloid deposits with only scattered CAA. (b) Western blot
analysis of human Aβ in APPwt brain in comparison to APPDutch brain.
Lanes 1–3, synthetic human Aβ. In amyloid-depositing APPwt mice (18
months), a substantial Aβwt1–40 and a somewhat weaker Aβwt1–42 band
were observed (lane 5), whereas in amyloid-depositing APPDutch mice (23
months), only AβDutch1–40 was detected (lane 4). Scale bar is 100 µm.
Figure 5 Predominant parenchymal amyloid deposition in APPDutch/PS45
double-transgenic mice. (a) Aβ-immunostaining of a 10-month-old
APPDutch/PS45 mouse shows extensive, predominantly diffuse, but also
some congophilic, parenchymal amyloid deposits with only scattered CAA. (b)
Western blot analysis of human Aβ in mouse brain immunoprecipitates. Lanes
1–3, synthetic human Aβ. Predepositing (4-month-old) APPDutch mouse
reveals only AβDutch1–40 (lane 4). In contrast, both AβDutch1–40 and
1–42 were detectable in a predepositing 2.5-month-old  APPDutch/PS45
mouse (lane 5) and a depositing 10-month-old APPDutch/PS45 mouse (lane
6). In order to show AβDutch1–40 and 1–42 as distinct bands, the sample
shown in lane 6 was highly diluted. Scale bar is 100 µm.
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logical response to vasodilation, and it can occlude affected vessels and
thus induce perivascular ischemia8,40,41. However, previous studies
have been limited by their reliance on end-stage human autopsy cases
and transgenic models that have severe parenchymal amyloidosis in
addition to CAA40–43. Our APPDutch model, which recapitulates well
human HCHWA-D, is likely to be a useful tool for the further study of
the pathogenic mechanisms by which CAA affects cognition and neu-
rodegeneration, as well as for the development of therapeutic strategies.
METHODS
Human patients. Tissue of frontal cortex and pial vessels was obtained at
autopsy from five HCHWA-D patients (50–76 years of age; postmortem delay
5–48 h). For comparison, cortical tissue from nine individuals with autopsy-
confirmed AD (61–93 years of age, postmortem delay 4–26 h) and two control
individuals (78 and 87 years of age, postmortem delay 4–11 h) was used.
Generation of transgenic mice. To generate Dutch-mutant APP transgenic
mice, human APP751 cDNA with the E693Q mutation was inserted into the
blunt-ended XhoI site of the vector pTSCα1 containing the murine Thy1.2
minigene44. After removal of vector sequences by NotI/PvuI digestion, linear
Thy1-APPconstructs were injected into C57BL/6J oocytes. Five positive trans-
genic founder mice (C57BL/6J-TgN(Thy1-APPE693Q)) were identified and
expression of human APP was assessed by western blot and immunohistochem-
istry. The two lines with the highest transgene expression (lines 23 and 33) were
used in this study (APPDutch mice). Expression levels in these lines are about
five times greater than endogenous APP levels (data not shown). The generation
of the wild-type human APP751 transgenic mice (C57BL/6J-TgN(Thy1-
APP)51) has been described previously45. Line 16 (APPwt mice), which has a
similar or slightly higher APP expression level than the APPDutch mice, was
used in this study. APPDutch/PS45 double-transgenic mice were obtained by
crossing APPDutch mice with mice overexpressing human G384A-mutated pre-
senilin-1 (PS1) under the control of the murine Thy1 promoter (B6,D2-
TgN(Thy1-PS1G384A)45). These PS45 mice were backcrossed to C57BL/6J for
more than seven generations prior to use. All mice analyzed were hemizygous
for the transgene(s) of interest. All animal experiments were in compliance with
protocols approved by the local Animal Care and Use Committees.
Histology and immunohistochemistry. Tissue was immersion-fixed in 4%
paraformaldehyde. Histology and immunohistochemistry were done on
either 4-µm-thick paraffin-embedded sections or 25-µm-thick free-floating
frozen sections. Aβ was immunostained with rabbit polyclonal antibody
NT12 (NT11), gifts of P .Paganetti (Basel, Switzerland)44 using standard
immunoperoxidase procedures with Elite ABC kits (Vector Laboratories),
with 3,3′-diaminobenzidine (Sigma) or Vector SG (Vector Laboratories) as
substrates. For specific staining of Aβx–40 or Aβx–42, we used rabbit antisera
R208 (R163) or R306 (R165), respectively46 (gift of P. Mehta, New York). All
Aβ antibodies recognized both Aβwt and AβDutch. Human APP (hAPP) was
visualized with polyclonal antibody A4CT (specific to the C-terminal 100
amino acids of APP; courtesy of K. Beyreuther, Heidelberg, Germany).
Microglia and astroglia were stained with rabbit polyclonal antibody to ion-
ized calcium binding adaptor molecule-1 (Iba-1)47 (courtesy of Y. Imai,
Tokyo) and rabbit polyclonal antibody to glial fibrillary acidic protein
(Dako), respectively. Double immunofluorescence labeling of Aβ and smooth
muscle cells was done for confocal microscopy. NT12 and mouse monoclonal
antibody to α-smooth muscle actin (A-2547, Sigma) followed by goat
anti–rabbit Alexa 568 and goat anti–mouse Alexa 488 (Molecular Probes)
were used. Staining with Congo red, Thioflavin S and Perls’ Prussian blue
reaction for ferric iron was done according to standard protocols41.
Electron microscopy. Mice were perfused with ice-cold PBS for 5 min.
Neocortical tissue pieces were removed and immersion-fixed in
4% paraformaldehyde and 0.5% glutaraldehyde at 4 °C. The tissue was then
postfixed in 1% osmium tetroxide in 0.1 M cacodylate buffer, dehydrated, and
then processed for Spurr embedding. Ultrathin sections were cut from selected
areas, stained with uranyl acetate and lead citrate, and then examined and
photographed with a Jeol JEM1011 electron microscope.
In situ hybridization. In situ hybridization for human APP was done as previ-
ously described44. In brief, a 33P-labeled oligonucleotide probe, 5′-AGC-
CTCTTCCTCTACCTCATCACCATCCTCATCGTCCTCG-3′, complementary
to the coding sequence of hAPP between nucleotides 859 and 898, was used at
a final concentration of 2 pmol/ml.
Western blot analysis. APP expression levels in transgenic mice were analyzed
using standard 8% SDS-polyacrylamide minigels followed by blotting and
antibody binding as described below. For analysis of Aβ, we used western blots
as previously described15. Briefly, samples of homogenized brain hemispheres
were subjected to SDS-PAGE using 10% T, 5% C bicine/Tris minigels contain-
ing 8 M urea in the separation gel. To detect Aβ in brains of predepositing
mice, we used immunoprecipitation with antibody 6E10. Proteins were trans-
ferred to a PVDF Immobilon-P membrane (Millipore) by semi-dry blotting,
incubated with antibody 6E10 (Signet) and visualized by chemiluminescence
(ECL, Amersham). Antibody 6E10 recognizes residues 1–17 of Aβ, and the
Dutch mutation at position 22 does not interfere with its binding. Synthetic
Aβwt1–40 and Aβw1–42 peptides were purchased from Bachem. Synthetic
AβDutch species were gifts ofJ. Ghiso (New York), G. Labeur (Ghent, Belgium)
and W. E. Van Nostrand (Stony Brook, New York, USA).
ELISA. Cerebral Aβ levels of patients and Aβ-depositing mice were assayed by
sandwich ELISA from formic acid–extracted sucrose homogenates prepared
from postmortem human cortical tissue or mouse hemi-brains lacking the
cerebellum, as previously described48. Aβ was captured with Aβ C-terminal
monoclonal antibodies that recognize exclusively either Aβx–40
(JRF/cAβ40/10) or Aβx–42 (JRF/cAβ42/26) and are detected with horseradish
peroxidase-conjugated JRF/Aβtot/17, which is specific to the N-terminal 16
residues of human Aβ48. Aβ levels in mice prior to amyloid deposition were
determined by preparing a sucrose homogenate from each hemibrain (with-
out cerebellum) and then extracting this in diethylamine (DEA), as previously
described49. Endogenous murine Aβ was similarly detected using DEA extrac-
tion and a murine-specific monoclonal antibody for detection (JRF/rAβ1-
15/2)49. ELISA results are reported as the mean ± s.e.m. in pmol Aβ per gram
of wet brain, based on standard curves using synthetic Aβ1–40 and Aβ1–42
peptide standards (American Peptide). The values were compared by non-
parametric Mann-Whitney U tests. All capture and detection antibodies were
a gift from M. Mercken (Johnson and Johnson Pharmaceutical Research and
Development/Janssen Pharmaceutica).
Note: Supplementary information is available on the Nature Neuroscience website.
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